Table 2. Characteristics of studies evaluating cancer prognosis included in the meta-analysis.
| Author | Country | Type of tumor | Ethnicity | Survival analysis | Mean/Median age (SD/range) | Stage | Cases | Genotypes | HR(95%CI) | Median follow-up (months) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OS (Univariable) | OS (Multivariable) | RFS (Univariable) | RFS (Multivariable) | ||||||||||
| Ryan 2012a | USA | CRC | AA | OS | 64.7 (11.7) | I-IV | 94 | CG vs. CC | 0.70 (0.39-1.27) | 0.72 (0.40-1.30) | - | - | 50.5 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GG vs. CC | 0.38 (0.13-1.13) | 0.36 (0.12-1.07) | - | - | |||||||||
| CG/GG vs. CC | 0.77 (0.53-1.12) | - | - | - | |||||||||
| Ryan 2012b | USA | CRC | Caucasian | OS | 64.7 (11.7) | I-IV | 145 | CG vs. CC | 1.25 (0.74-2.10) | 1.41 (0.81-2.44) | - | - | 50.5 |
| GG vs. CC | 3.54 (1.38-9.12) | 2.95 (1.13-7.71) | - | - | |||||||||
| CG/GG vs. CC | 1.24 (0.87-1.77) | - | - | - | |||||||||
| Xing 2012 | China | CRC | Chinese | OS, RFS | 59.4 (22-90) | 0-IV | 408 | GC vs. CC | 0.99 (0.60-1.64) | - | 0.85 (0.57-1.27) | - | 23 |
| GG vs. CC | 1.11 (0.65-1.88) | - | 1.21 (0.80-1.81) | - | |||||||||
| CG/GG vs. CC | 1.03 (0.64-1.66) | - | 1.03(0.71-1.49) | - | |||||||||
| Zheng 2013a | China | NPC | Chinese | RFS | 54 (21-82) | I-IV | 873 | CG vs. CC | - | - | 1.41 (0.89-2.04) | 1.45 (0.92-2.18) | 37.2 |
| GG vs. CC | - | - | 2.02 (1.29-3.16) | 2.05 (1.35-3.21) | |||||||||
| GC/GG vs. CC | - | - | 1.61 (1.13-2.29) | 1.68 (1.18-2.61) | |||||||||
| Zheng 2013b | China | NPC | Chinese | RFS | 52 (19-87) | I-IV | 828 | CG vs. CC | - | - | 1.55 (1.03-2.15) | 1.62 (1.11-2.19) | 34.8 |
| GG vs. CC | - | - | 2.21 (1.49-3.24) | 2.24 (1.45-3.38) | |||||||||
| GC/GG vs. CC | - | - | 1.65 (1.17-2.39) | 1.71 (1.23-2.31) | |||||||||
| Jiao 2014 | China | BC | Chinese | OS | 51 (29-83) | I-III | 196 | CG vs. CC | 1.42 (0.65-3.11) | - | - | - | 114 |
| GG vs. CC | 1.32 (0.72-2.41) | - | - | - | |||||||||
| CG/GG vs. CC | 1.34 (0.76-2.38) | - | - | - | |||||||||
| CC/CG vs. GG | 1.21 (0.61-2.40) | - | - | - | |||||||||
| Ma 2016 | China | HCC | Chinese | OS | 50 (20-81) | I-IV | 361 | GG vs. CC | 1.67 (1.11-2.49) | 1.61 (1.07-2.40) | - | - | 53 |
| CG/GG vs. CC | 1.47 (1.03-2.09) | 1.40 (0.98-2.00) | - | - | |||||||||
| CC/CG vs. GG | 0.76 (0.57-1.01) | 0.76 (0.57-1.01) | - | - | |||||||||
| Xia 2016 | China | NSCLC | Chinese | OS | 57.12 (11.47) | I-IV | 584 | CG vs. GG | 1.07 (0.84-1.37) | 0.98 (0.76-1.25) | - | ||
| GG vs. CC | 1.00 (0.74-1.36) | 0.99 (0.73-1.34) | |||||||||||
| Ying 2016 | China | CRC | Chinese | OS, RFS | 60.80 (13.03) | 0-III | 1218 | CG vs. CC | 0.89 (0.70-1.13) | 0.89 (0.70-1.14) | 0.92 (0.76-1.11) | 0.93 (0.76-1.13) | 26 |
| GG vs. CC | 1.03 (0.75-1.41) | 1.10 (0.80-1.52) | 1.04 (0.81-1.34) | 1.08 (0.83-1.40) | |||||||||
| CG/GG vs. CC | 0.92 (0.73-1.15) | 0.94 (0.75-1.18) | 0.94 (0.79-1.14) | 0.97 (0.80-1.16) | |||||||||
| CC/CG vs. GG | 0.90 (0.68-1.19) | 0.85 (0.64-1.12) | 0.91 (0.72-1.15) | 0.88 (0.70-1.10) | |||||||||
| G vs. C | 0.99 (0.85-1.16) | 1.02 (0.87-1.19) | 1.00 (0.89-1.13) | 1.02 (0.90-1.16) |
CRC: colorectal cancer; NPC: nasopharyngeal carcinoma; BC: breast cancer; HCC:hepatocellular carcinoma; NSCLC: non-small cell lung cancer; AA: African-American; OS: overall survival; RFS: recurrence-free survival.